Primary SS disease-specific outcomes measures in systemic and non-systemic patients
| Not currently systemic patients N=250 | Currently systemic patients N=145 | p Value* | |||
|---|---|---|---|---|---|
| Physician outcome measures | |||||
| ESSDAI | 4 (1–10) | 6.1±6.7 | 10 (6–17) | 13.0±10.1 | <0.0001 |
| SCAI | 6 (4.5–8) | 6.4±3.4 | 10 (6–15) | 11.3±7.0 | <0.0001 |
| SSDAI | 1 (0–2) | 1.0±1.0 | 2 (1–3) | 1.9±1.6 | <0.0001 |
| PhGA | 2 (1–4) | 2.7±1.8 | 4 (3–6) | 4.4±2.4 | <0.0001 |
| Patient-centred measures | |||||
| ESSPRI | 5.7 (4–7.3) | 5.5±2.3 | 6.7 (5.0–7.7) | 6.3±2.1 | 0.0008 |
| SSI | 4.6 (3.1–6.5) | 4.7±2.3 | 5.1 (3.4–6.8) | 5.1±2.2 | 0.14 |
| PROFAD | 3.9 (2.6–5.5) | 4.1±2.1 | 5 (3.2–6.4) | 4.9±2.3 | 0.0016 |
| PGA | 6 (4–8) | 5.9±2.6 | 7 (5–8) | 6.3±2.6 | 0.06 |
Results are presented as median (interquartile range), or means±SD.
*Scores were compared to those of patients without systemic involvement using Wilcoxon's test.
ESSDAI, EULAR Sjögren's Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren's Syndrome Patient-Reported Index; PGA, patient global assessment; PhGA, physician global assessment; PROFAD, Profile of Fatigue and Discomfort; SCAI, Sjögren's Systemic Clinical Activity Index; SSDAI, Sjögren's Syndrome disease activity index; SSI, Sicca Symptoms Inventory.